A Hub for Regulatory, Compliance, and Business Insights
The legal and regulatory landscape surrounding peptides continues to evolve rapidly, creating new compliance considerations, business opportunities, and potential risks for companies across the industry. From FDA policy and compounding requirements to enforcement activity, advertising, telehealth, litigation, and emerging business models, staying informed is critical for organizations operating in the peptide marketplace.
Frier Levitt’s Peptide Legal & Regulatory Resource Center brings together our latest insights on the issues shaping this evolving industry. Explore articles and legal updates, webinars and events, media coverage featuring Frier Levitt attorneys, and other resources designed to help peptide manufacturers, compounding pharmacies, telehealth platforms, healthcare providers, wellness businesses, investors, and other industry stakeholders stay informed about important legal, regulatory, and business developments.
Featured Articles
- Trump Administration’s Proposed Peptide Enforcement Discretion Policy: What Compounding Pharmacies and Peptide Suppliers Need to Know – October 14, 2026
The Trump administration is reportedly considering a significant change in the federal government’s approach to peptide compounding. According to recent reports, the administration is exploring an interim enforcement discretion policy… - FDA Warning Letter Signals New Enforcement Theory for Compounded GLP-1 Combination Products – September 25, 2026
The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Empower Clinic Services, LLC (dba Empower Pharmacy) addressing its compounding of tirzepatide and semaglutide combination products… - Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook
– August 18, 2026
Eli Lilly and Company (“Lilly”) filed six federal lawsuits on August 12, 2026, against businesses it accuses of illegally selling retatrutide, the company’s experimental “triple-agonist” obesity drug that has not yet been approved by the U.S. Food and Drug Administration (FDA) or any other regulator worldwide…
Featured Media Coverage
- Edgar J. Asebey Featured in The Capitol Forum on Eli Lilly’s Retatrutide Classification Fight – October 1, 2026
Eli Lilly’s legal battle with the U.S. Food and Drug Administration (FDA) over the classification of its next-generation GLP-1 drug, retatrutide, could have significant implications for drug exclusivity, compounding pharmacies and future GLP-1 development… - Edgar J. Asebey Interviewed by Peptides Business Wire: “Clarity in peptides? Don’t hold your breath” – October 1, 2026
Frier Levitt Partner Edgar J. Asebey spoke with Peptides Business Wire about the evolving regulatory landscape for peptides, including the FDA Pharmacy Compounding Advisory Committee’s (PCAC) recent recommendations, increased enforcement activity, and new legal strategies being pursued by pharmaceutical manufacturers… - FDA Advisory Committee Recommends Six Peptides for 503A Compounding: What Businesses Need to Know – September 17, 2026
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) recently recommended that six of seven peptides under review be added to the 503A Bulks List, a potentially significant development for compounding pharmacies, prescribers, and businesses operating in the rapidly evolving peptide industry…
Featured Webinars
- The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models – August 20, 2026
Pharmacy compounding remains one of the most closely watched areas of FDA enforcement, particularly as compounded GLP-1s and peptides continue to draw regulatory and manufacturer attention… - FDA’s July Peptide Review: What the PCAC Meeting Means for Peptide Compounding – July 22, 2026
The peptide industry is approaching one of its most consequential regulatory moments in recent years. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) considers whether seven peptides should be added to the 503A Bulks List.… - Legal Insights into GLP-1 and Peptide Compounding in 2026 – March 18, 2026
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape…
Meet Our Team
Edgar J. Asebey
Partner
973-852-8392
easebey@frierlevitt.com
Jesse C. Dresser
Partner
973-852-8361
jdresser@frierlevitt.com
Guilherme Ferrari Faviero
Senior Associate
332-205-6585
gferrari@frierlevitt.com
Arielle T. Miliambro
Partner
973-852-8379
amiliambro@frierlevitt.com
Melissa Roy
Associate
862-210-2064
mroy@frierlevitt.com
Brandon S. Zarsky
Partner
973-852-8398
bzarsky@frierlevitt.com
